What are the administration guidelines for erythromycin (E‑Mycin)?

Erythromycin (E-Mycin) Administration Guidelines

Erythromycin should be administered at 40-50 mg/kg/day divided into 4 doses for children over 1 month (maximum 2 g/day) and 2 g/day in 4 divided doses for adults, with a 14-day treatment course recommended for pertussis. 1

Age-Specific Dosing

Infants Under 1 Month (Neonates)

• Not preferred due to significant risk of infantile hypertrophic pyloric stenosis (IHPS) 1
• Azithromycin is the recommended alternative macrolide for this age group 1
• If erythromycin must be used when azithromycin is unavailable: 40-50 mg/kg/day in 4 divided doses 1
• Critical safety requirement: These infants must be monitored closely for IHPS 1
• The risk-benefit calculation favors treatment in neonates exposed to pertussis, as the mortality risk from pertussis outweighs IHPS risk 1

Infants Over 1 Month and Children

• 40-50 mg/kg/day in 4 divided doses 1
• Maximum daily dose: 2 g/day 1
• Treatment duration: 14 days (for pertussis; shorter courses of 7-10 days have been associated with relapses) 1

Adults

• 2 g/day in 4 divided doses 1
• Treatment duration: 14 days for pertussis 1
• For community-acquired pneumonia with atypical pathogens: 40 mg/kg/day in 4 doses (alternative formulation: erythromycin ethylsuccinate 400 mg 4 times daily) 2, 3

Available Formulations

Erythromycin is available in multiple oral formulations 1, 4:

• Erythromycin base: tablets (250,333,500 mg), delayed-release tablets, delayed-release capsules 4
• Erythromycin ethylsuccinate: suspension (200,400 mg/5 mL), oral drops (100 mg/2.5 mL), chewable tablets (200 mg), tablets (400 mg) 4
• Erythromycin estolate: suspension (125,250 mg/5 mL) 4
• Erythromycin stearate: tablets (250,500 mg) 4
• Parenteral formulations: erythromycin gluceptate (1000 mg), erythromycin lactobionate (500,1000 mg) 4

Administration Techniques to Minimize Side Effects

Gastrointestinal Tolerance Strategies

Gastrointestinal irritation (epigastric distress, abdominal cramps, nausea, vomiting, diarrhea) is the most common adverse effect and is dose-related 1:

• Enteric-coated tablets and ester derivatives (e.g., ethylsuccinate) can be taken with food to minimize side effects 1
• Limit daily doses to less than 4 g when possible 5
• Consider temporarily decreasing the total daily dose if intolerance occurs 5
• Use small doses of liquid suspension every 2-4 hours 5
• Take medication with milk or food 5
• Drink water every 15 minutes, 2-3 times after each dose 5
• Give oral doses after meals 4

Parenteral Administration

For intravenous erythromycin lactobionate 4:

• Administer as continuous drip or slow infusion over ≥60 minutes 4
• Dosing: 15-20 mg/kg (maximum 4 g) IV in divided doses every 6 hours for adults 4
• Pediatric dosing: 20-40 mg/kg/day IV in divided doses every 6 hours 4
• Oral therapy should replace IV therapy as soon as clinically feasible 4
• Continuous infusion at 1 g per 12 hours produces adequate serum levels after initial 8 hours 6

Critical Safety Considerations

Infantile Hypertrophic Pyloric Stenosis (IHPS)

• Highest risk: neonates during the month after erythromycin administration 1
• In one cohort study: 7 cases out of 157 erythromycin-exposed infants versus 0 cases out of 125 unexposed infants (relative risk: infinity, 95% CI = 1.7-infinity) 1
• IHPS has occurred in breastfeeding infants whose mothers took erythromycin 1
• Healthcare providers must inform parents about IHPS risks and counsel them about warning signs 1

Contraindications

Erythromycin is absolutely contraindicated in 1:

• History of hypersensitivity to any macrolide agent 1
• Concomitant use with astemizole, cisapride, pimazole, or terfenadine (risk of QT prolongation, cardiac arrest, torsades de pointes, ventricular arrhythmias) 1

Hepatotoxicity

• Erythromycin estolate may cause cholestatic jaundice, though hepatotoxicity is uncommon (2% of cases) 4
• Use with caution in patients with hepatic disease 4
• Adjust dose in renal failure 4

Drug Interactions

Erythromycin is a potent inhibitor of cytochrome P450 enzyme system (CYP3A subclass) 1:

High-risk CYP3A substrates requiring caution 1:

• Alfentanil, bromocriptine, cyclosporine, carbamazepine, cilostazol, disopyramide
• Dihydroergotamine, ergotamine, lovastatin, simvastatin, methylprednisolone
• Quinidine, rifabutin, vinblastine, tacrolimus
• Triazolo-benzodiazepines (triazolam, alprazolam) and related benzodiazepines
• Sildenafil

Additional documented interactions (not thought to be CYP3A-mediated) 1:

• Zidovudine, hexobarbital, phenytoin, valproate, theophylline, digoxin, oral anticoagulants

High potential for interaction with many antiretrovirals 4

Special Populations

Pregnancy

• FDA Pregnancy Category B 1
• Animal reproduction studies have not demonstrated fetal risk, but no adequate well-controlled human studies exist 1

Neonates

• Use with extreme caution due to IHPS risk 4
• Life-threatening episodes of ventricular tachycardia associated with prolonged QTc interval have been reported 4

Clinical Pearls

• Twice-daily dosing (2 x 500 mg) has been shown effective for streptococcal tonsillitis with similar efficacy to four-times-daily dosing, though this is not the standard recommendation for pertussis 7
• The advanced generation macrolides (azithromycin, clarithromycin) have lower incidence of gastrointestinal side effects and less frequent dosing, improving compliance 8
• For patients requiring long-term therapy, low-dose erythromycin (400-600 mg daily) has been used successfully in diffuse panbronchiolitis 9
• Erythromycin has prokinetic effects on gastrointestinal motility, which may contribute to both therapeutic effects and side effects 5, 10